Development of a Corticosteroid-Immunosuppressed Mouse Model to Study the Pathogenesis and Therapy of Influenza-Associated Pulmonary Aspergillosis

J Infect Dis. 2023 Apr 12;227(7):901-906. doi: 10.1093/infdis/jiad001.

Abstract

Influenza-associated pulmonary aspergillosis (IAPA) is a feared complication in patients with influenza tracheobronchitis, especially those receiving corticosteroids. Herein, we established a novel IAPA mouse model with low-inoculum Aspergillus infection and compared outcomes in mice with and without cortisone acetate (CA) immunosuppression. CA was an independent predictor of increased morbidity/mortality in mice with IAPA. Early antifungal treatment with liposomal amphotericin B was pivotal to improve IAPA outcomes in CA-immunosuppressed mice, even after prior antiviral therapy with oseltamivir. In summary, our model recapitulates key clinical features of IAPA and provides a robust preclinical platform to study the pathogenesis and treatment of IAPA.

Keywords: amphotericin B; aspergillosis; corticosteroids; influenza; mouse model; oseltamivir; pneumonia.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Animals
  • Antifungal Agents / therapeutic use
  • Aspergillosis* / drug therapy
  • Aspergillus fumigatus
  • Humans
  • Influenza, Human* / complications
  • Influenza, Human* / drug therapy
  • Mice
  • Pulmonary Aspergillosis* / complications
  • Pulmonary Aspergillosis* / drug therapy

Substances

  • Antifungal Agents
  • Adrenal Cortex Hormones